Vaccitech

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 9, 2023

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.

Key Points: 
  • OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.
  • “The third quarter of 2023 was a period of solid progress for the Company.
  • We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio.
  • Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023.

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Retrieved on: 
Wednesday, September 13, 2023

Details are as follows:

Key Points: 
  • Details are as follows:
    To register for the event, click here .
  • The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease.
  • Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.
  • A live Q&A session will follow the formal presentations.

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 10, 2023

Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.

Key Points: 
  • Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
  • The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
  • Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
  • Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Retrieved on: 
Wednesday, June 21, 2023

WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial that has been expanded to include a PD-1 monoclonal antibody, nivolumab. Nivolumab is approved for a number of types of cancer under the brand name, Opdivo®. The objective of the additional treatment arm is to assess if a low dose of nivolumab, in combination with the booster dose(s) of Vaccitech plc’s (Nasdaq: VACC) VTP-300, will further stimulate immune mediated reduction of HBsAg after the initial treatment with AB-729 and ongoing nucleos(t)ide analogue (NA) therapy in patients with chronic hepatitis B infection (cHBV).

Key Points: 
  • Nivolumab is approved for a number of types of cancer under the brand name, Opdivo®.
  • The Phase 2a triple combination clinical trial, AB-729-202, has been expanded to evaluate the safety, antiviral activity and immunogenicity of nivolumab plus Vaccitech’s VTP-300, an antigen-specific immunotherapeutic encoding multiple hepatitis B antigens, following treatment with AB-729 and ongoing NA therapy.
  • Enrollment is complete in the original portion of the clinical trial, which is currently evaluating the triple combination of AB-729, NA therapy and VTP-300 or placebo.
  • Preliminary data from the original portion of the trial is expected in the second half of 2023.

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Retrieved on: 
Monday, June 12, 2023

PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence).

Key Points: 
  • PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence).
  • VTP-850 is a next-generation prostate cancer immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA.
  • The first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain.
  • “When the immune system targets multiple molecules on tumor cells, it is generally harder for tumor cells to escape destruction by the immune system.”

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Friday, May 12, 2023

In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.

Key Points: 
  • In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.
  • In April 2023, we announced the planned retirement of Chris Ellis, Chief Operating Officer, effective October 31, 2023.
  • Cash position: As of March 31, 2023, cash was $191.3 million, compared to $194.4 million as of December 31, 2022.
  • Revenues: Revenue were $0.5 million in the first quarter of 2023 compared to $15.0 million in the comparable period of the previous year.

British Innovation Fund founders, Milltrust Ventures, bring in Asian investors to successful Series B funding of one of its leading British impact investments companies, Polymateria.

Retrieved on: 
Tuesday, May 2, 2023

This round saw Polymateria raise an additional £20 million in capital to help enter new markets and accelerate the commercialisation of its ground-breaking technology at scale.

Key Points: 
  • This round saw Polymateria raise an additional £20 million in capital to help enter new markets and accelerate the commercialisation of its ground-breaking technology at scale.
  • First invested into by Milltrust and its clients, as part of Green Earth Ventures, a silo of British Innovation Fund II, Polymateria is a pioneering biotech company whose technology was first developed by scientists from Imperial College London in 2016.
  • Polymateria provides a patented time controlled biological additive for incorporation into conventional plastic manufacturing processes to create biodegradable plastic packaging - a genuine world first.
  • Through the creation of British Innovation Fund II, Milltrust continues to identify winning companies originating out of UK universities, providing its expertise to assist the roll out of impactful solutions which benefit humankind.

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

Retrieved on: 
Monday, April 17, 2023

The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.

Key Points: 
  • The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.
  • “The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV (hrHPV) infections.
  • Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions,” said Meg Marshall, CMO of Vaccitech.
  • In addition, intracellular cytokine staining data from the active groups showed both CD4 and CD8 responses.

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Retrieved on: 
Tuesday, March 28, 2023

VTP-300 was observed to induce meaningful, sustained reductions of Hepatitis B surface antigen (HBsAg) in patients with chronic HBV.

Key Points: 
  • VTP-300 was observed to induce meaningful, sustained reductions of Hepatitis B surface antigen (HBsAg) in patients with chronic HBV.
  • The final results of the immunology assays are currently being analyzed and the full data, including tolerability and immunogenicity results, will be presented at the upcoming EASL Congress, June 21-24, 2023.
  • “The safety data and HBsAg reductions in the HBV002 study are very encouraging and we look forward to sharing the full data set, including immune responses, at the EASL conference,” said Bill Enright, CEO of Vaccitech.
  • “Less than 10% of people with chronic HBV reach a functional cure with current therapies.

UK leadership in health, food and sustainability prompts Milltrust to launch follow-on university venture fund.

Retrieved on: 
Monday, March 27, 2023

The fund will target high-impact, early-stage companies with links to UK University science and innovation.

Key Points: 
  • The fund will target high-impact, early-stage companies with links to UK University science and innovation.
  • A particular focus will be directed toward global food systems and health, which have been identified as key post-pandemic priorities, both for the UK and internationally.
  • Dr Bernard Ng, a medical and clinical affairs leader and former Chief Medical Officer at Bayer consumer division, joins Milltrust as Chief Scientific Officer.
  • Other investments include Attomarker, a unique blood testing diagnostic platform revolutionising personalised medicine, and Polymateria, a technology developed at Imperial College, developing biodegradable plastic as a solution to the plastic waste crisis.